SHC Sotera Health Co Insider Trading

Director Pincus & Co. Warburg sells entire 19,102,952 share stake in SHC for $289.8M at $15.17; stock down 4.7% in 30 days, -23.1% from 52-week high.

Pincus & Co. Warburg liquidated his complete position in Sotera Health—19,102,952 shares for $289,753,575.94 total value—on 2026-05-13, leaving zero post-transaction holdings. The sale occurred at $15.17 while the stock has since declined to $15.27 (current price is -23.1% from its 52-week high of $19.85) and has fallen 4.7% in the 30 days since the transaction. Across his prior five trades specifically at SHC, Pincus achieved well-timed exits on 2 of 5 occasions (measured by negative 90-day returns post-sale). The complete exit warrants investor attention given the large absolute dollar value and the concentration risk this insider was previously carrying.

Warburg Pincus & Co. exits SHC entirely, selling 19,102,952 shares at $15.17 for $289,753,575.94, reducing stake to 0.

Warburg Pincus & Co. (Director) sold its entire position of 19,102,952 shares of Sotera Health Co (SHC) at $15.17 on 2026-05-13 for total proceeds of $289,753,575.94, leaving 0 shares post-transaction — a complete exit from the company. This sale occurred with SHC trading -23.1% below its 52-week high of $19.85, and the stock has declined -4.7% over the prior 30 days and -10.8% over the prior 90 days. Across Warburg Pincus & Co.'s cross-ticker sell history, the 90-day well-timed rate stands at 50.00%, and prior sells at SHC specifically showed mixed outcomes: the March 2026 sells produced a 30-day return of -2.0% and a 90-day return of +1.4%, while the December 2025 sells showed a 30-day return of +8.3% and a 90-day return of -3.9%. The complete liquidation of a 19.10M share position by a Director-level holder is a material ownership event regardless of prior timing patterns, and investors should note that SHC trades at a P/E of 37.24 against a market cap of $4.4B with quarterly net income of $26,589,000.

GTCR Investment XI LLC sold 12,735,301 shares of SHC at $15.17, exiting position entirely for $193,169,045.57

GTCR Investment XI LLC completely exited its 12,735,301-share position in Sotera Health (SHC) on 2026-05-13, selling at $15.17 per share for total proceeds of $193,169,045.57. This represents a full liquidation of the director's holdings, distinct from partial reductions. The company trades at a P/E of 37.24 with net income of $26,589,000.00 on revenue of $280,045,000.00 (annual growth +5.7%), suggesting valuation elevation relative to earnings. SHC has declined 23.1% from its 52-week high and 4.7% over the last 30 days; the broader market context shows this sale occurred amid downward price momentum. At the same-ticker level, GTCR's prior 5 trades at SHC showed mixed timing: only 2 of 5 prior sales were well-timed at the 90-day mark, indicating inconsistent execution at this security. The full exit signal warrants investor attention given its scale and the current valuation and price-action environment.

Warburg Pincus sells 15,000,000 SHC shares for $229.0M at $15.27; exits -44.0% of position as stock trades -27.3% from 52-week high

Warburg Pincus substantially reduced its SHC position by 15,000,000 shares (44.0% of prior holdings) on 2026-03-06 at $15.27 per share, generating $229,050,000.00 in proceeds. The timing is notable: the sale occurred when the stock was -27.3% below its 52-week high and has declined -20.8% in the 30 days since the transaction and -16.8% over 90 days. Across his prior SHC trades (5 prior transactions), 2 of 4 measurable historical sales showed negative 90-day returns after sale (well-timed outcomes), though the other 2 showed positive returns. The current price of $14.06 sits 7.9% below the execution price, partially validating this exit point relative to recent momentum. At a P/E of 45.35 and 5.7% annual revenue growth, the company commands a premium valuation that may weigh on near-term upside.

GTCR Investment XI LLC sold 10,000,000 shares of Sotera Health at $15.27 on 2026-03-06 ($152.7M), reducing stake by 44.0%

GTCR Investment XI LLC, a director holding, liquidated 10,000,000 shares (44.0% of pre-transaction holdings), reducing its stake from 22,735,301 to 12,735,301 shares at $15.27 per share for $152,700,000.00 total. The sale occurs at a price that is now -27.3% from the 52-week high of $19.35, and the stock has declined -20.8% in the 30 days following the transaction and -16.8% over 90 days. In the same-ticker history at SHC, GTCR's prior 5 sales yielded mixed timing outcomes: 3 of the 5 prior sells proved well-timed at the 90-day mark (stock fell after the sale), though 2 were poorly timed. The cross-ticker track record shows a 66.67% well-timed rate on 6 prior sells (average -4.5% 90-day return), suggesting this insider has a history of selling before declines. The substantial reduction in an already-large institutional position warrants attention to the company's fundamentals and the director's forward guidance.

Warburg Pincus (Director) sells 15.00M SHC shares at $15.27; holdings drop 44.0% to 19.10M shares as stock falls -27.3% from 52-week high.

Warburg Pincus sold 15,000,000 shares of Sotera Health on 2026-03-06 at $15.27, reducing its stake by -44.0% from 34,102,952 to 19,102,952 shares, representing a $229,050,000.00 reduction in holdings. The stock has declined to $14.06, now -27.3% from its 52-week high of $19.35, with a -20.8% drop over 30 days and -16.8% over 90 days, suggesting the market has repriced the company post-transaction. At the same ticker, Warburg Pincus' prior four measurable sales showed mixed timing: 2 of 4 were well-timed at the 90-day mark (2025-11-10 sales both showed +7.9% at 30d and +13.4% at 90d, indicating the stock rose after those sales), while 2 of 4 were poorly timed (2025-12-03 sales both returned +8.3% at 30d but -3.9% at 90d). The current transaction's large scale and the stock's sharp subsequent decline warrant monitoring to assess whether this sale signals a change in confidence or market conditions at Sotera Health.

CEO Petras sold entire 750,000 share position for $12.3M at $16.45 on 2025-12-08

Michael B. Petras Jr., Chairman & CEO of Sotera Health Co, executed 3 separate sales totaling 750,000 shares for $12,337,500.00, eliminating his entire holdings at a blended average price of $16.45. The sale occurred at a price 2.6% below the current price of $16.89 and within the stock's 52-week range. His cross-ticker track record shows 1 prior sell with a 90-day return of -21.9%, achieving a 100.00% well-timed rate on sells (measured by post-sale stock declines); his prior trade at SHC on 2024-03-04 was similarly well-timed at the 90-day mark with -21.9% subsequent return. The complete liquidation of a CEO's holdings, combined with a historical pattern of selling before declines at this specific ticker, represents material insider activity that material participants should evaluate against Sotera's current fundamentals (P/E: 84.45, annual revenue growth +4.9%, net income $48,400,000.00) and the stock's recent 7.3% rise over 30 days.

Warburg Pincus sells 9,720,000 SHC shares for $158.7M; holdings drop 22.2% to 34.10M

Warburg Pincus (Director) executed a substantial sale of 9,720,000 shares at $16.33 on 2025-12-03, reducing holdings by 22.2% to 34,102,952 shares and generating $158,727,600.00 in proceeds. This represents a meaningful reduction in the director's position at Sotera Health, which trades near its 52-week high of $17.48 at a current price of $16.75. The transaction occurs at a valuation where the company's P/E of 83.75 and recent quarterly revenue of $311,312,000.00 with net income of $48,400,000.00 merit scrutiny; the director's multi-transaction history at SHC shows that 0 of 2 prior measurable sells were well-timed (stock rose 9.6% over 90 days following the September sells), suggesting the insider's exits at this ticker have not anticipated subsequent declines. Investors should monitor whether this large exit—combined with the company's rich valuation and modest 4.9% annual revenue growth—reflects evolving confidence in the equity or is driven by other portfolio considerations.

WARBURG PINCUS & CO. sells 9,720,000 shares of SHC at $16.33; holdings drop to 34.10M (-22.2%)

WARBURG PINCUS & CO. executed a substantial sale of 9,720,000 shares at $16.33 on 2025-12-03, reducing its stake from 43,822,952 to 34,102,952 shares and cutting holdings by 22.2%. The transaction was completed at $16.33, which is near the current price of $16.75 and well within the 52-week range of $9.80–$17.48 (within 4.2% of the 52-week high). At the same-ticker level, the insider's prior two measurable sales at SHC (both on 2025-09-05) saw the stock subsequently post positive 90-day returns of +9.6%, indicating those earlier exits were not well-timed. The cross-ticker track record shows a 66.67% well-timed rate on 9 prior sells, though that metric does not predict performance at this specific ticker. Given the substantial reduction in holdings, near-peak pricing at transaction time, and the company's elevated P/E of 83.75 against modest revenue growth of 4.9%, the transaction merits investor attention but remains within normal portfolio management parameters.

GTCR Investment XI LLC sold 6,480,000 shares of SHC at $16.33 on 2025-12-03; stake reduced from 29.22M to 22.74M shares (-22.2%)

GTCR Investment XI LLC, a director, executed a material reduction of its SHC position by selling 6,480,000 shares (totaling $105,818,400.00) on 2025-12-03 at $16.33 per share, lowering its stake from 29,215,301 shares to 22,735,301 shares—a -22.2% decrease. The sale occurs at $16.33 while the stock currently trades at $16.75 and stands within 4.2% of its 52-week high ($17.48), near the upper end of its 52-week range ($9.80–$17.48). Reviewing GTCR's same-ticker history at SHC, 2 of 3 measurable prior sells (2025-09-05 and 2024-09-06) showed negative 90-day returns, indicating some pattern of exiting before subsequent weakness; however, this current sale price is already near the 52-week peak, limiting the headroom for further appreciation. The company itself shows a high P/E of 83.75 alongside modest annual revenue growth of +4.9%, suggesting valuation is already stretched relative to earnings generation.